scholarly journals Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector

2006 ◽  
Vol 194 (12) ◽  
pp. 1638-1649 ◽  
Author(s):  
Andrew T. Catanzaro ◽  
Richard A. Koup ◽  
Mario Roederer ◽  
Robert T. Bailer ◽  
Mary E. Enama ◽  
...  
Keyword(s):  
Recombinant Adenovirus ◽  
Phase 1 ◽  
Adenovirus Vector ◽  
Candidate Vaccine ◽  
Recombinant Adenovirus Vector ◽  
Hiv 1

Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome

2011 ◽  
Vol 158 (1-2) ◽  
pp. 154-160 ◽  
Author(s):  
Takayuki Suzuki ◽  
Tomomi Sasaki ◽  
Koyori Yano ◽  
Fuminori Sakurai ◽  
Kenji Kawabata ◽  
...  
Keyword(s):  
Production System ◽  
Viral Genome ◽  
Recombinant Adenovirus ◽  
Adenovirus Vector ◽  
Size Limit ◽  
Recombinant Adenovirus Vector

A simplified cloning strategy for the generation of an endothelial cell selective recombinant adenovirus vector

2006 ◽  
Vol 135 (1) ◽  
pp. 127-135 ◽  
Author(s):  
Chitladda Mahanivong ◽  
Jörg A. Krüger ◽  
Dafang Bian ◽  
Ralph A. Reisfeld ◽  
Shuang Huang
Keyword(s):  
Endothelial Cell ◽  
Recombinant Adenovirus ◽  
Adenovirus Vector ◽  
Cloning Strategy ◽  
Recombinant Adenovirus Vector

Regulation of N-myc gene expression: use of an adenovirus vector to demonstrate posttranscriptional control

1990 ◽  
Vol 10 (12) ◽  
pp. 6700-6708
Author(s):  
L E Babiss ◽  
J M Friedman
Keyword(s):  
Recombinant Adenovirus ◽  
Wilms Tumor ◽  
Fetal Brain ◽  
Adenovirus Vector ◽  
Cell Types ◽  
Adult Brain ◽  
Posttranscriptional Control ◽  
Equivalent Rate ◽  
Myc Gene ◽  
Recombinant Adenovirus Vector

We present evidence that differences in the levels of N-myc mRNA among different cell types are the result of posttranscriptional control. First, we noted that while steady-state mouse N-myc mRNA could be detected only in fetal mouse brain, it was transcribed at an equivalent rate in adult brain, liver, spleen, and placenta and in fetal brain. Similarly, the human N-myc gene was transcribed at an equivalent rate in HeLa cells, which do not accumulate this RNA in the cytoplasm, and cell lines G401 (a Wilms tumor-derived cell line) and SKNMc (established from a primitive neuroepithelioma), which do express N-myc RNA. As expected, the N-myc promoter functioned at equivalent rates, as demonstrated by the level of a reporter gene, when introduced into these cell types by using a recombinant adenovirus vector. The suggestion that posttranscriptional mechanisms control the level of this RNA was supported by the observation that sequences in the N-myc third exon specifically decreased the level of E1A mRNA when these sequences were placed downstream of the E1A promoter in a recombinant adenovirus. Finally, we further localized these sequences to a 600-bp fragment of the third exon by introducing various subclones of this sequence downstream of the E1A promoter in both viral and plasmid vectors.

scholarly journals Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

PLoS ONE ◽  
2010 ◽  
Vol 5 (1) ◽  
pp. e8617 ◽  
Author(s):  
Sandhya Vasan ◽  
Sarah J. Schlesinger ◽  
Yaoxing Huang ◽  
Arlene Hurley ◽  
Angela Lombardo ◽  
...  
Keyword(s):  
Phase 1 ◽  
Candidate Vaccine ◽  
Clade C ◽  
Hiv 1

Expression of human α1-antitrypsin using a recombinant adenovirus vector

FEBS Letters ◽  
1990 ◽  
Vol 267 (1) ◽  
pp. 60-62 ◽  
Author(s):  
P. Gilardi ◽  
M. Courtney ◽  
A. Pavirani ◽  
M. Perricaudet
Keyword(s):  
Recombinant Adenovirus ◽  
Adenovirus Vector ◽  
Recombinant Adenovirus Vector
Sign in / Sign up

Export Citation Format

Share Document